GlucoTrack Inc Cash Flow Conversion Efficiency
GlucoTrack Inc cash flow conversion efficiency. Based on the latest financial reports, GlucoTrack Inc (GCTK) has a cash flow conversion efficiency ratio of 2.077x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($-1.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GlucoTrack Inc (2011–2025)
Cash flow conversion efficiency of GlucoTrack Inc from 2011 to 2025. This chart illustrates how GlucoTrack Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GlucoTrack Inc stock quote for real-time trading data and today's change.
GlucoTrack Inc Cash Flow Conversion Ratio Explained
GlucoTrack Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GlucoTrack Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlucoTrack Inc ranked by their cash flow conversion efficiency. Also see GlucoTrack Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HODL SPAC EUROPE AB
F:NW1
|
0.039x |
|
Synectics plc
LSE:SNX
|
-0.035x |
|
Anexo Group Plc
LSE:ANX
|
-0.057x |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
3.264x |
|
Inotiv, Inc.
NASDAQ:NOTVQ
|
-0.014x |
|
GRIT Real Estate Income Group
LSE:GR1T
|
0.058x |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
0.022x |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
-0.145x |
Annual Cash Flow Conversion Efficiency for GlucoTrack Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of GlucoTrack Inc from 2011 to 2025. Review how financially flexible is GlucoTrack Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.83 Million | $-15.24 Million | -5.389x | -660.90% |
| 2024-12-31 | $-13.00 Million | $-12.49 Million | 0.961x | +146.84% |
| 2023-12-31 | $3.20 Million | $-6.56 Million | -2.051x | +32.34% |
| 2022-12-31 | $1.23 Million | $-3.73 Million | -3.032x | -314.66% |
| 2021-12-31 | $5.16 Million | $-3.77 Million | -0.731x | -87.58% |
| 2020-12-31 | $8.98 Million | $-3.50 Million | -0.390x | -114.12% |
| 2019-12-31 | $-1.41 Million | $-3.90 Million | 2.761x | +62.18% |
| 2018-12-31 | $-2.87 Million | $-4.89 Million | 1.703x | +378.73% |
| 2017-12-31 | $-16.57 Million | $-5.90 Million | 0.356x | -26.69% |
| 2016-12-31 | $-10.95 Million | $-5.31 Million | 0.485x | -25.92% |
| 2015-12-31 | $-6.97 Million | $-4.57 Million | 0.655x | -5.86% |
| 2014-12-31 | $-4.83 Million | $-3.36 Million | 0.696x | +139.18% |
| 2013-12-31 | $-11.06 Million | $-3.22 Million | 0.291x | -93.63% |
| 2012-12-31 | $-503.07K | $-2.30 Million | 4.566x | +330.72% |
| 2011-12-31 | $968.24K | $-1.92 Million | -1.979x | -- |
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications… Read more